Fengjiao Yuan

Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy

Limin Zhu, Haijun Wang, Qing Fan, 2021, Journal of Nanobiotechnology.

Her3-specific affibody mediated tumor targeting delivery of ICG enhanced the photothermal therapy against Her3-positive tumors.

Shuhui Zheng, Qing Fan, Dianlong Jia, 2022, International journal of pharmaceutics.

NTN4 as a prognostic marker and a hallmark for immune infiltration in breast cancer

Mingliang Gu, Fengjiao Yuan, Conghui Tian, 2022, Scientific Reports.

ICG-Dimeric Her2-Specific Affibody Conjugates for Tumor Imaging and Photothermal Therapy for Her2-Positive Tumors.

Huimin Liu, Qing Fan, Dianlong Jia, 2022, Molecular pharmaceutics.

Coupling EGFR-antagonistic affibody enhanced therapeutic effects of cisplatin liposomes in EGFR-expressing tumor models.

Yujiao Yang, Dianlong Jia, Fengjiao Yuan, 2021, Journal of pharmaceutical sciences.

Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models.

Yujiao Yang, Qing Fan, Dianlong Jia, 2020, International journal of pharmaceutics.

Fusion of an EGFR-antagonistic affibody enhances the anti-tumor effect of TRAIL to EGFR positive tumors.

Renming Liu, Dianlong Jia, Fengjiao Yuan, 2022, International journal of pharmaceutics.

Codelivery of TRAIL and Mitomycin C via Liposomes Shows Improved Antitumor Effect on TRAIL-Resistant Tumors.

Dianlong Jia, Fengjiao Yuan, Rui Wang, 2023, Molecular pharmaceutics.

Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.

Jianmei Wei, Xiaona Lu, Dianlong Jia, 2023, Journal of controlled release : official journal of the Controlled Release Society.